On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > FY2026 Drug Pricing Reform
FY2026 Drug Pricing Reform
-
Romiplate to See Steepest Cut in April Market Expansion Re-Pricing
March 5, 2026
-
Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead
January 19, 2026
-
Chuikyo OKs 3.5% Minimum NHI Price Hike, Sets Grace Period for New AG Pricing
January 19, 2026
-
Bosulif, 4 Other Drugs Escape April Re-Pricing as “Spillover” Scrapped; Lixiana, Entresto Brace for Cuts
January 19, 2026
-
Japan Sets New Pricing Rules for Conditionally Approved Regenerative Medicines, Starting with Elevidys
January 15, 2026
-
Gist of FY2026 Drug Pricing Reform Outline
December 26, 2025
-
Japan Puts CEA Expansion on Hold, Sets 6-Month “Technical Discussions”
December 26, 2025
-
Chuikyo OKs FY2026 Drug Pricing Reform Outline, Scraps “Spillovers” but Adds New Follow-Up Rules
December 26, 2025
-
Japan Ministers Agree to Scrap “Spillover” Rule, Plan Wider CEA Price Cuts
December 25, 2025
-
Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests
December 15, 2025
-
Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
-
2024 Reform Spurred New Development Activity, 20 Projects Entered Clinic: Industry Poll
December 11, 2025
-
Regenerative Medicine Group Accepts Deferred Debate on Market Expansion Re-Pricing
December 11, 2025
-
Wholesalers Urge Price Hikes on Sub-20-Yen Drugs as Negative Margins Mount
December 11, 2025
-
MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?
December 4, 2025
-
MHLW Proposes Pricing New AGs and Bio-AGs on Par with Originators
December 4, 2025
-
FY2026 Reform Roadmap Keeps Key Drug Pricing Issues on Ice, Snubs Many Industry Requests: Chuikyo
December 4, 2025
-
Average NHI-Market Price Gap Hits Fresh Record Low at 4.8%
December 3, 2025
-
Chuikyo Discusses Lower Prices for Low-Novelty Drugs, PMP Criteria, Re-Pricing
November 20, 2025
-
Chuikyo Split over How to Ease Negative Margins
November 20, 2025
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…